Accro Bioscience Funding: $100M Raised, Series C (2026)
Accro Bioscience is based in Suzhou, China. It has raised $100M in total funding. Latest round: Series C. Backed by Morningside Ventures.
Accro Bioscience funding overview
Accro Bioscience is based in Suzhou, China. Accro Bioscience has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in May 2026. The round record for Accro Bioscience runs through 2026; nothing later has been disclosed. Investors on record include Morningside Ventures.
Accro Bioscience at a glance
Total raised
$100M
Latest round
Series C
Latest round date
May 2026
Headquarters
Suzhou, China
Notable investors
Morningside Ventures
Frequently asked about Accro Bioscience funding
How much has Accro Bioscience raised?
Accro Bioscience has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Accro Bioscience?
Morningside Ventures are named among the investors backing Accro Bioscience.
What was the latest Accro Bioscience funding round?
The most recent disclosed round is a Series C, announced in May 2026.
Where is Accro Bioscience based?
Accro Bioscience is based in Suzhou, China.
When did Accro Bioscience last raise?
The last disclosed Accro Bioscience round closed in May 2026 at Series C.
Totals shown for Accro Bioscience aggregate every disclosed round on file. To see how that compares, browse the companies in Suzhou and the investors behind them below.
